ulrich medical grows for the 15th year in succession
The medical technology manufacturer ulrich medical, including its subsidiaries, closed the 2024 financial year with a revenue of €163 million. Compared with the previous year, this translates to a 10 percent growth in revenue. In addition, it also recorded a 20 percent increase in profit. This means that ulrich medical has increased its revenue for the 15th year in succession, further underscoring its position as a reliable partner in the medical technology industry.
The contrast media injectors for CT and MRI product group was a key driver of the increase in revenue at Ulrich Medical last year.
Klaus Kiesel, CEO and Chair of the Executive Board, commented: “Our profitable growth is the result of the realization of long-term business strategies.” Co-CEO Friedrich von Rechteren added: “With it, we are proving that focusing consistently on “Made in Germany” and being successful on an international scale are not mutually exclusive.” The three subsidiaries in France, Spain, and the USA are all contributing to this growth. One key driver for success in the past year was the contrast media injectors for CT and MRI product group. The France subsidiary in particular managed to increase its revenue in this product group by approx. 73 percent, corresponding to a market share growth of seven percentage points. As such, Ulrich Medical has now achieved a market share of considerably more than 25 percent in Europe. In order to satisfy the growing demand, the company recently began renting additional production premises close to the city of Ulm.
Wichtiger Arbeitgeber in der Region
With over 600 employees in total, of which more than 550 are at the headquarters in Ulm, ulrich medical is a significant employer in the region. In 2024, the company celebrated the anniversaries of 35 staff members working there for 10, 20, 25, 30, or 35 years. Klaus Kiesel affirmed: “The long-term loyalty of our employees is confirmation of the fact that we set standards not only in medical technology but also as an employer. Our growth is thanks to a highly skilled team that gives its all day in, day out.” Friedrich von Rechteren added: “We are also planning to maintain our growth curve both in Germany and abroad in 2025.”
Further information can be found at https://www.ulrichmedical.com/en.
